Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
The Journal of Urology (Impact Factor: 3.75). 10/2006; 176(4 Pt 1):1415-9. DOI: 10.1016/j.juro.2006.06.002
Source: PubMed

ABSTRACT We report on the long-term results and late toxicity outcomes of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
Between 1996 and 2000 a total of 561 patients with clinically localized prostate cancer were treated with intensity modulated radiation therapy. All patients were treated to a dose of 81 Gy prescribed to the planning target volume. Prostate specific antigen relapse was defined according to the American Society for Therapeutic Radiology and Oncology consensus and Houston definitions (absolute nadir plus 2 ng/ml dated at the call). Median followup was 7 years (range 5 to 9).
The 8-year actuarial PSA relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the American Society for Therapeutic Radiology and Oncology definition were 85%, 76% and 72%, respectively (p <0.025). The 8-year actuarial prostate specific antigen relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the Houston definition were 89%, 78% and 67%, respectively (p = 0.0004). The 8-year actuarial likelihood of grade 2 rectal bleeding was 1.6%. Three patients (0.1%) experienced grade 3 rectal toxicity requiring either 1 or more transfusions or a laser cauterization procedure. No grade 4 rectal complications have been observed. The 8-year likelihood of late grade 2 and 3 (urethral strictures) urinary toxicities were 9% and 3%, respectively. Among patients who were potent before intensity modulated radiation therapy, erectile dysfunction developed in 49%. The cause specific survival outcomes for favorable, intermediate and unfavorable risk cases were 100%, 96% and 84%, respectively.
These long-term results confirm our previous observations regarding the safety of high dose intensity modulated radiation therapy for clinically localized prostate cancer. Despite the application of high radiation doses, the incidence of rectal bleeding at 8 years was less than 2%. Despite the increased conformality of the dose distribution associated with intensity modulated radiation therapy, excellent long-term tumor control outcomes were achieved.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Bislang sind radikale Prostatektomie und Strahlentherapie gleichwertige Verfahren hinsichtlich ihrer onkologischen Wirksamkeit, sofern die Strahlentherapie adäquat dosiert erfolgt. Es stehen die interstitielle Brachytherapie, die perkutane Radiotherapie oder Kombinationen zur Verfügung. Für die Weiterentwicklung strahlentherapeutischer Verfahren ergibt sich insbesondere für Patienten mit intermediärem Risiko ein technologisches Optimierungsfenster über die Dosiseskalation. Neuere Entwicklungen wie die intensitätsmodulierte und bildgeführte Strahlentherapie erlauben eine Applikation höherer Dosen ohne eine relevante Steigerung der Nebenwirkungsraten. Darüber hinaus scheint für definierte Patientenkollektive eine additive Hormontherapie verbesserte Kontrollraten zu erreichen. Nach R1-Resektion verbessert eine adjuvante Bestrahlung das rezidivfreie Überleben; bei später auftretenden lokoregionären Rezidiven ist eine Radiatio die bislang einzige kurative Option. Radiotherapy is a well-accepted treatment modality for patients with localised prostate cancer. Provided that radiotherapy is applied with a sufficient radiation dose, it is as effective as radical prostatectomy. Different radiation modalities are available (interstitial brachytherapy, external beam radiotherapy or a combination of both). Various new developments will further increase the value of radiation-based approaches. In this regard, a wider use of intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) will result in higher treatment doses with even lower toxicity rates. Combinations of radiotherapy and hormonal ablation improve local control rates in defined groups of patients. After prostatectomy with positive surgical margins, adjuvant radiotherapy improves disease-free survival rates; in cases of local relapse, salvage radiotherapy is the only potentially curative treatment approach.
    Der Urologe 08/2008; 47(9):1245-1255. · 0.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite excellent success rates with radical prostatectomy and radiotherapy for the treatment of prostate cancer, a significant number of patients will experience a rise in their serum prostate specific antigen (PSA) level. A variety of salvage options in this scenario have been investigated and the choice to pursue surveillance, single therapy or combination therapy depends on clinical assessment of risk and location of tumor recurrence. After radical prostatectomy, for example, patients with low risk local disease may not require secondary therapy or may benefit from salvage radiotherapy. Those with higher risk disease, based on PSA kinetics and tumor pathology may require systemic androgen deprivation therapy (ADT) with or without radiotherapy. Local recurrence after radiotherapy has the options of cryotherapy, brachytherapy or salvage surgery. ADT can also be applied in these patients at high risk of disease progression and cancer-specific mortality. Risk assessment in these settings is paramount as all secondary therapy options for prostate cancer have potential side effects that may significantly affect quality of life. We review the literature and discuss the current methods of risk assessment and the treatment options in prostate cancer once primary therapy fails.
    The Canadian Journal of Urology 01/2008; 14 Suppl 1:2-9. · 0.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: New treatments are introduced routinely into clinical practice without rigorous economic analysis. The specific aim of this study was to examine the cost effectiveness of proton beam radiation compared with current state-of-the art therapy in the treatment of patients with prostate cancer. Materials and A Markov model was informed with cost, freedom from biochemical failure (FFBF), and utility data obtained from the literature and from patient interviews to compare the cost effectiveness of 91.8 cobalt gray equivalent (CGE) delivered with proton beam versus 81 CGE delivered with intensity-modulated radiation therapy (IMRT). The length of how many years the model was run, patient's age, probability of FFBF after treatment with proton beam therapy and IMRT, utility of patients treated with salvage hormone therapy, and treatment cost were tested in sensitivity analyses. Analysis at 15 years resulted in an expected mean cost of proton beam therapy and IMRT of $63,511 and $36,808, and $64,989 and $39,355 for a 70-year-old and 60-year-old man respectively, with quality-adjusted survival of 8.54 and 8.12 and 9.91 and 9.45 quality-adjusted life-years (QALY), respectively. The incremental cost effectiveness ratio was calculated to be $63,578/QALY for a 70-year-old man and $55,726/QALY for a 60-year-old man. Even when based on the unproven assumption that protons will permit a 10-Gy escalation of prostate dose compared with IMRT photons, proton beam therapy is not cost effective for most patients with prostate cancer using the commonly accepted standard of $50,000/QALY. Consideration should be given to limiting the number of proton facilities to allow comprehensive evaluation of this modality.
    Journal of Clinical Oncology 09/2007; 25(24):3603-8. · 18.04 Impact Factor


Available from